Table 4. . Adverse events for the entire subject cohort.
Adverse events | Total (n = 106) | |
---|---|---|
All grades | Grade 3/4 | |
Total | 96 (90.6%) | 3 (2.8%) |
Fatigue/weakness | 58 (54.7%) | 1 (0.9%) |
Diarrhea/colitis | 16 (15.1%) | 0 (0%) |
Hypophysitis | 0 (0%) | 0 (0%) |
Thyroid | 11 (10.4%) | 0 (0%) |
Adrenal insufficiency | 1 (0.9%) | 0 (0%) |
Pneumonitis | 6 (5.7%) | 2 (1.8%) |
Rash/pruritis | 17 (16.0%) | 0 (0%) |
Liver | 2 (1.8%) | 0 (0%) |
Nephropathy | 9 (8.5%) | 0 (0%) |
Dyspnea | 23 (21.7%) | 0 (0%) |
Edema | 11 (10.4%) | 0 (0%) |
Constipation | 9 (8.5%) | 0 (0%) |
Nausea/vomiting | 14 (13.2%) | 0 (0%) |
A fib | 1 (0.9%) | 0 (0%) |
Arthralgia/myalgia | 10 (9.4%) | 0 (0%) |
Pneumonia/upper respiratory infection | 12 (11.3%) | 0 (0%) |
Flu like symptoms | 2 (1.8%) | 0 (0%) |
Hypersensitivity reaction | 1 (0.9%) | 0 (0%) |
Other | 10 (9.4%) | 0 (0%) |
Discontinued due to adverse event | 20 (18.9%) |